Kottil W. Rammohan

Dr. Kottil W. Rammohan


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2023 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
SDSilvia R. Delgado
Silvia R. Delgado
SFSimon Faissner
Simon Faissner
RLRalf A. Linker
Ralf A. Linker
KRKottil W. Rammohan
Kottil W. Rammohan
The recent success of anti-CD20 monoclonal antibody therapies in the treatment of multiple sclerosis (MS) has highlighted the role of B cells in the pathogenesis of MS. In people with MS, the inflammatory characteristics of B-cell activity are elevated, leading to increased pro-inflammatory cytokine release, diminished anti-inflammatory cytokine production and an accumulation of pathogenic B cells in the cerebrospinal fluid. Rituximab, ocrelizumab, ofatumumab, ublituximab and BCD-132 are anti-CD20 therapies that are either undergoing clinical development, or have been approved, for the treatment of MS. Despite CD20 being a common target for these therapies, differences have been reported in their mechanistic, pharmacological and clinical characteristics, which may have substantial clinical implications. This narrative review explores key characteristics of these therapies. By using clinical trial data and real-world evidence, we discuss their mechanisms of action, routes of administration, efficacy (in relation to B-cell kinetics), safety, tolerability and convenience of use. Clinicians, alongside patients and their families, should consider the aspects discussed in this review as part of shared decision-making discussions to improve outcomes and health-related quality of life for people living with MS.

28 November 2020 in Drugs
Verified
Journal Article
Open access
PDF file
KRKottil W. Rammohan
Kottil W. Rammohan
PCPatricia K. Coyle
Patricia K. Coyle
ESElke Sylvester
Elke Sylvester
AGAndrew Galazka
Andrew Galazka
FDFernando Dangond
Fernando Dangond
TLThomas P. Leist
Thomas P. Leist
Cladribine is a purine nucleoside analog initially developed in the 1970s as a treatment for various blood cancers. Due to the molecule’s ability to preferentially reduce T and B lymphocytes, it has been developed into an oral formulation for the treatment of multiple sclerosis (MS). The unique proposed mechanism of action of cladribine allows for the therapy to be delivered orally over two treatment-week cycles per year, one cycle at the beginning of the first month and one cycle at the beginning of the second month of years 1 and 2, with the potential for no further cladribine treatment required in years 3 and 4. This review summarizes the clinical development program for cladribine tablets in patients with MS, including the efficacy endpoints and results from the 2-year phase III CLARITY study in patients with relapsing–remitting MS (RRMS), the 2-year CLARITY EXTENSION study, and the phase III ORACLE-MS study in patients with a first clinical demyelinating event at risk for developing MS. Efficacy results from the phase II ONWARD study, in which cladribine tablets were administered as an add-on to interferon-β therapy in patients with RRMS, are also summarized. A review of all safety data, including lymphopenia, infections, and malignancies, is provided based on data from all trials in patients with MS, including the initial parenteral formulation studies. Based on these data, cladribine tablets administered at 3.5 mg/kg over 2 years have been approved across the globe for various forms of relapsing MS. The development of cladribine tablets for the treatment of multiple sclerosis: a comprehensive review (MP4 279143 kb)

18 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NGNeeta Garg
Neeta Garg
EPElizabeth Jordan Padron
Elizabeth Jordan Padron
KRKottil W. Rammohan
Kottil W. Rammohan
CGCourtney Frances Goodman
Courtney Frances Goodman
Bruton’s tyrosine kinase (BTK) is an important protein belonging to the tyrosine kinase family that plays a key role in the intracellular signaling and proliferation, migration, and survival of normal and malignant B-lymphocytes and myeloid cells. Understanding the role of BTK in the B-cell signaling pathway has led to the development of BTK inhibitors (BTKi) as effective therapies for malignancies of myeloid origin and exploration as a promising therapeutic option for other cancers. Given its central function in B-cell receptor signaling, inhibition of BTK is an attractive approach for the treatment of a wide variety of autoimmune diseases that involve aberrant B-cell function including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS). Here, we review the role of BTK in different cell signaling pathways, the development of BTKi in B-cell malignancies, and their emerging role in the treatment of MS and other autoimmune disorders.

9 August 2021 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
GGGavin Giovannoni
Gavin Giovannoni
GCGiancarlo Comi
Giancarlo Comi
KRKottil W. Rammohan
Kottil W. Rammohan
PRPeter Rieckmann
Peter Rieckmann
FDFernando Dangond
Fernando Dangond
PVPatrick Vermersch
Patrick Vermersch
Introduction In the Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study, cladribine tablets significantly reduced relapse rates and improved findings on magnetic resonance imaging versus placebo in patients with relapsing multiple sclerosis. In the CLARITY Extension study, treatment with cladribine tablets for 2 years followed by placebo for 2 years produced similar clinical benefits to 4 years of cladribine tablets. The objective of this exploratory post hoc analysis was to evaluate long-term disease stability (assessed by the Expanded Disability Status Scale [EDSS] score) after treatment with cladribine tablets. Methods Patients enrolled into CLARITY Extension who were previously randomized to cladribine tablets 3.5 mg/kg in the CLARITY study were included in this post hoc analysis. Two treatment groups were investigated—patients randomized to cladribine tablets 3.5 mg/kg in CLARITY and thereafter randomized to placebo in CLARITY Extension (the CP3.5 group) or to cladribine tablets 3.5 mg/kg in CLARITY Extension (the CC7 group). In each treatment group, EDSS scores at 6-month intervals, EDSS score improvement/worsening each year, and time to 3- and 6-month confirmed EDSS progression were assessed from CLARITY baseline over 5 years of follow-up (including a variable bridging interval between studies). All analyses are descriptive, and no statistical comparisons were performed for between-treatment group differences. Results The median (95% confidence interval [CI]) EDSS score for patients in the CP3.5 group at 5 years was 2.5 (2.0–3.5) compared with 3.0 (2.5–3.5) at baseline. In the CC7 group, median EDSS score (95% CI) at 5 years was 2.0 (2.0–3.0) compared with 2.5 (2.5–3.0) at baseline. During year 5 for the CP3.5 group, and based on changes in minimum score each year, EDSS score stability was observed in 53.9% of patients, improvement in 21.3%, and worsening in 24.7%. In the CC7 group, EDSS score remained stable in 66.1%, improved in 18.1%, and worsened in 15.8% of patients. Over 70% of patients in both treatment groups did not show 3- or 6-month confirmed EDSS progression at 5 years from CLARITY baseline. Conclusions These findings confirm long-term beneficial effects on disability afforded by either the recommended dose of cladribine tablets over 4 years (cumulative dose, 3.5 mg/kg) or a higher cumulative dose. Trial Registration ClinicalTrials.gov NCT00213135 (CLARITY); NCT00641537 (CLARITY Extension).

1 January 2012 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
KRKottil W. Rammohan
Kottil W. Rammohan
GGGavin Giovannoni
Gavin Giovannoni
GCGiancarlo Comi
Giancarlo Comi
SCStuart Cook
Stuart Cook
PRPeter Rieckmann
Peter Rieckmann
CGCLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group
CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group

12 December 2013 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
NUNida Usmani
Nida Usmani
MMMicheline McCarthy
Micheline McCarthy
KRKottil W. Rammohan
Kottil W. Rammohan
MOMelissa R. Ortega
Melissa R. Ortega